On November 21, 2023 Orion reported that two new Phase 3 clinical trials to evaluate the safety and efficacy of ODM-208 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) have been posted to the ClinicalTrials.gov website (Press release, Orion, NOV 21, 2023, View Source [SID1234637869]). The studies are not yet recruiting patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Further information is available on ClinicalTrials.gov

A study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (study identifier: NCT06136650)
A study of MK-5684 Versus Alternative NHA in mCRPC (study indentifier: NCT06136624)
About ODM-208/MK-5684

ODM-208 (or MK-5684) is an investigational oral, non-steroidal and selective inhibitor of the CYP11A1 enzyme discovered and developed by Orion for the treatment of hormone-dependent cancers, such as prostate cancer. ODM-208 is being developed through a collaboration with MSD (tradename of Merck & Co., Inc. Rahway NJ USA).